Predictive Value of Neutrophil Percentage to Albumin Ratio (NPAR) and Platelet-to-Lymphocyte Ratio (PLR) in Methotrexate Treatment Outcomes for Ectopic Pregnancy

SITKI ÖZBİLGEÇ , FATİH AKKUŞ , Emin Erhan Dönmez

  • FATİH AKKUŞ: Kütahya Şehir Hastanesi
  • Emin Erhan Dönmez: İSTANBUL EĞİTİM VE ARAŞTIRMA HASTANESİ
  • Year : 2025
  • Vol : 41
  • Issue : 1
  •  Page : 24-28
ABSTRACT
Objective: This study investigates the predictive role of the Neutrophil Percentage to Albumin Ratio (NPAR), Platelet-to-Lymphocyte Ratio (PLR), and Systemic Immune-Inflammation Index (SII) in determining methotrexate (MTX) treatment outcomes in patients with ectopic pregnancy (EP).
Materials and Methods: We conducted a retrospective analysis of 166 patients with ectopic pregnancy treated with MTX at a tertiary hospital between January 1, 2020, and May 1, 2024. Patients were categorized into two groups: those achieving successful MTX treatment and those experiencing treatment failure, necessitating additional MTX doses or surgical intervention. NPAR, PLR, and SII values were calculated from baseline blood parameters and analyzed to assess their predictive value. Statistical analyses included logistic regression and ROC curve analysis to determine optimal cutoff values. Results: NPAR and PLR were significant predictors of MTX treatment outcomes, with higher values correlating with increased likelihood of MTX failure (p <0.05). In contrast, SII did not show a significant association with treatment outcomes. ROC analysis showed that NPAR and PLR had satisfactory predictive performance, with AUC values of 0.777 (95% CI: 0.690-0.864) and 0.659 AUC (95% CI: 0.548-0.770), respectively. Optimal cutoff values for NPAR and PLR were determined to guide clinical decision-making.
Conclusion: This study identified NPAR and PLR as valuable markers for predicting MTX treatment outcomes in ectopic pregnancy, whereas SII was not predictive in this context. NPAR and PLR may aid in early identification of patients at risk for MTX treatment failure, enabling more personalized and effective management of ectopic pregnancy. Further research is needed to validate these findings in larger, prospective studies.
Keywords: Ectopic pregnancy, methotrexate treatment, neutrophil percentage to albumin ratio (NPAR), platelet-to-lymphocyte ratio (PLR), systemic Inflammatory markers
Cite this Article As : Ozbilgec S, Akkus F, Donmez EE. The Predictive Role of Neutrophil Percentage to Albumin Ratio (NPAR) and Systemic Inflammatory Markers in Methotrexate Treatment Outcomes for Ectopic Pregnancy. Selcuk Med J 2025;41(1): 24-28

Download Citation: Endnote/Zotero/Mendeley (RIS) RIS File

Download Citation: BibTeX BibTeX File

Conflict of interest : The authors declare that they have no conflict of interest.
This article is published under the CC BY-NC 4.0 license.
Selcuk Medical Journal
2025, Vol. 41 (1)
ISSN: 1017-6616
E-ISSN: 2149-8059
Received : , Accepted : , Published Online :

References

  1. 1- Mullany K, Minneci M, Monjazeb R, O CC. Overview of ectopic pregnancy diagnosis, management, and innovation. Womens Health (Lond). 2023;19:17455057231160349. doi: 10.1177/17455057231160349
  2. 2- Moakes CA, Tong S, Middleton LJ, Duncan WC, Mol BW, Whitaker LHR, Jurkovic D, Coomarasamy A, Nunes N, Holland T, Clarke F, Sutherland LC, Doust AM, Daniels JP, Horne AW. Gefitinib and methotrexate to resolve tubal ectopic pregnancy: the GEM3 RCT. Southampton (UK): National Institute for Health and Care Research; 2023 Jun. PMID: 37459432. Doi:10.3310/NNZF037
  3. 3- Cem DAĞDELEN, Yusuf DAL, Fatih AKKUŞ, Mehmet Okan ÖZKAYA, Evrim ERDEMOĞLU. Treatment Management of Tubal Ectopic Pregnancy: A 4-Year Retrospective Single Center Experience. Türk üreme tıbbı ve cerrahisi dergisi (Online). 2022;6(2):167–72.
  4. 4- Seyfettinoglu S, Adıguzel FI. Prediction of Tubal Rupture in Ectopic Pregnancy Using Methotrexate Treatment Protocols and Hematological Markers. J Clin Med. 2023 Oct 11;12(20):6459. doi: 10.3390/jcm12206459. PMID: 37892597; PMCID: PMC10607125.
  5. 5- Dereli ML, Savran Üçok B, Özkan S, Sucu S, Topkara S, Fıratlıgil FB, Ercan EE, Uğur M, Akdaş Reis Y, Engin Üstün Y. The importance of blood-count-derived inflammatory markers in predicting methotrexate success in patients with tubal ectopic pregnancy. Int J Gynaecol Obstet. 2024 Nov;167(2):789-796. doi: 10.1002/ijgo.15696. Epub 2024 May 21. PMID: 38773760.
  6. 6- Liu CF, Chien LW. Predictive Role of Neutrophil-Percentage-to-Albumin Ratio (NPAR) in Nonalcoholic Fatty Liver Disease and Advanced Liver Fibrosis in Nondiabetic US Adults: Evidence from NHANES 2017-2018. Nutrients. 2023 Apr 14;15(8):1892. doi: 10.3390/nu15081892. PMID: 37111111; PMCID: PMC10141547.
  7. 7- Yu Y, Zhong Z, Yang W, Yu J, Li J, Guo X, Chen J, Mao H, Li Z. Neutrophil Percentage-to-Albumin Ratio and Risk of Mortality in Patients on Peritoneal Dialysis. J Inflamm Res. 2023 Dec 21;16:6271-6281. doi: 10.2147/JIR.S437256. PMID: 38146321; PMCID: PMC10749557.
  8. 8- American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Gynecology. ACOG Practice Bulletin No. 193: Tubal Ectopic Pregnancy. Obstet Gynecol. 2018 Mar;131(3): e91-e103. doi: 10.1097/AOG.0000000000002560. Erratum in: Obstet Gynecol. 2019 May;133(5):1059. doi: 10.1097/AOG.0000000000003269. PMID: 29470343.
  9. 9-Dinc K, Issın G. Novel marker to predict rupture risk in tubal ectopic pregnancies: the systemic immune-inflammation index. Ginekologia Polska. 2023;94(4):320-325. Doi:10.5603/GP.a2023.0010
  10. 10- Reis YA, Akay A, Diktaş EG, Özkan M, Öztürk N, Özkan D, Çakır BT, Erkaya S. Prediction of Rupture by Complete Blood Count in Tubal Ectopic Pregnancies Treated with a Single-Dose Methotrexate Protocol. Rev Bras Ginecol Obstet. 2023 Sep;45(9):e503-e510. doi: 10.1055/s-0043-1772485. Epub 2023 Oct 16. PMID: 37846182; PMCID: PMC10579924.
  11. 11- Sarikaya S, Uysal E, Günenç O. Can the systemic immune inflammation index predict the treatment of ectopic pregnancy? Arch Obstet Gynecol. 2023;4(2):28-33. Doi:10.33696/Gyneacology.4.039